Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland by the U.S. Food and Drug Administration (FDA) which started on January 10, 2024, has been concluded. Following the FDA inspection, Alvotech received a form 483 with one observation. Alvotech expects to provide the FDA with a re

Related Keywords

Ukraine ,Indonesia ,India ,Iceland ,Philippines ,Switzerland ,Canada ,Singapore ,Japan ,Israel ,Reykjavik ,C10 ,Bangladesh ,Cambodia ,China ,Australia ,United Kingdom ,Yangtze River ,China General ,United States ,Thailand ,Malaysia ,Taiwan ,South Korea ,Pakistan ,Vietnam ,Republic Of ,New Zealand ,Hong Kong ,Robert Wessman ,Saval Latin America ,Africa ,Fuji Pharma Co Ltd Japan ,Oaktree Acquisition Corp ,Kamada Ltd ,Teva Pharmaceutical Industries Ltd ,Teva Pharmaceuticals ,Drug Administration ,Alvotech Holdings ,Lotus Pharmaceuticals Co Ltd ,Pharma Corporation Canada ,Yangtze River Pharmaceutical Group Co Ltd ,South America ,Teva Pharmaceutical Industries ,Advanz Pharma ,Cipla Med Pro ,Yangtze River Pharmaceutical ,Middle East ,North Africa ,Abdi Ibrahim ,Mega Labs ,Latin America ,Private Securities Litigation Reform Act ,Oaktree Acquisition ,Note Regarding Forward Looking ,Alvotech ,Forward Looking Statements ,